-
Je něco špatně v tomto záznamu ?
Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review
A. Dima, MC. Vonk, A. Garaiman, BE. Kersten, R. Becvar, M. Tomcik, AM. Hoffmann-Vold, I. Castellvi, JT. Jaime, M. Brzosko, M. Milchert, D. Krasowska, M. Michalska-Jakubus, P. Airo, M. Matucci-Cerinic, C. Bruni, M. Iudici, J. Distler, AM....
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, systematický přehled
- MeSH
- antinukleární protilátky * krev MeSH
- DNA-topoisomerasy I imunologie MeSH
- dospělí MeSH
- klinická relevance MeSH
- lidé středního věku MeSH
- lidé MeSH
- průřezové studie MeSH
- senioři MeSH
- systémová sklerodermie * imunologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- systematický přehled MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: The anti-Nucleolar Organizer Region 90 antibodies (NOR90) are rare antinuclear antibodies (ANA) reported in systemic sclerosis (SSc). Especially due to low prevalence, the clinical relevance of NOR90 in SSc remains uncertain. OBJECTIVES: To analyze the clinical associations of NOR90 in patients with SSc in a multicentric cohort. METHODS: Post-hoc, cross-sectional study of prospectively collected data from the European Scleroderma Trials and Research (EUSTAR) database, with additional information on NOR90. Further, we performed a systematic literature search, using the terms "systemic sclerosis" and "NOR90" across three databases: Medline via PubMed, Scopus, and Thomson Reuters' Web of Science Core Collection, from inception to November 1st, 2023. RESULTS: Overall, 1318 patients with SSc were included (mean age 58.3 ± 13.7 years, 81.3 % female), of whom 44 (3.3 %) were positive for NOR90. Of these, 32 were also positive for one of the SSc-criteria antibodies: 9/44 (20.5 %) for anti-topoisomerase I, 18/42 (42.9 %) for anti-centromere, and 5/40 (12.5 %) for anti-RNA polymerase III. NOR90-positive patients were more frequently female, had lower modified Rodnan skin score (mRSS), and lower prevalence of upper and lower gastrointestinal (GI) symptoms compared to NOR90-negative patients. In multivariable analysis, NOR90 remained significantly associated with lower mRSS and less frequent GI symptoms. The literature search identified 17 articles, including a total number of 87 NOR90-positive out of 3357 SSc patients, corresponding to an overall prevalence of 2.6 %. CONCLUSION: To our best knowledge, this is the largest SSc cohort tested for NOR90 to date, confirming the NOR90 prevalence in SSc patients is around 3 %.
Department of Rheumatology Firoozgar Hospital Beh Afarin street Tehran Iran
Department of Rheumatology Rikshospitalet University Hospital Sognsvannveien 20 0027 Oslo Norway
Rheumatology Unit Geneva University Hospitals 1211 Geneva 14 Switzerland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019931
- 003
- CZ-PrNML
- 005
- 20241024110854.0
- 007
- ta
- 008
- 241015e20240409ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejim.2024.03.035 $2 doi
- 035 __
- $a (PubMed)38599922
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Dima, A $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland; Department of Rheumatology, Colentina Clinical Hospital, 19-21 Stefan cel Mare, 020125 Bucharest, Romania. Electronic address: alina_dima@outlook.com
- 245 10
- $a Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review / $c A. Dima, MC. Vonk, A. Garaiman, BE. Kersten, R. Becvar, M. Tomcik, AM. Hoffmann-Vold, I. Castellvi, JT. Jaime, M. Brzosko, M. Milchert, D. Krasowska, M. Michalska-Jakubus, P. Airo, M. Matucci-Cerinic, C. Bruni, M. Iudici, J. Distler, AM. Gheorghiu, H. Poormoghim, F. Motta, M. De Santis, M. Parvu, O. Distler, C. Mihai
- 520 9_
- $a BACKGROUND: The anti-Nucleolar Organizer Region 90 antibodies (NOR90) are rare antinuclear antibodies (ANA) reported in systemic sclerosis (SSc). Especially due to low prevalence, the clinical relevance of NOR90 in SSc remains uncertain. OBJECTIVES: To analyze the clinical associations of NOR90 in patients with SSc in a multicentric cohort. METHODS: Post-hoc, cross-sectional study of prospectively collected data from the European Scleroderma Trials and Research (EUSTAR) database, with additional information on NOR90. Further, we performed a systematic literature search, using the terms "systemic sclerosis" and "NOR90" across three databases: Medline via PubMed, Scopus, and Thomson Reuters' Web of Science Core Collection, from inception to November 1st, 2023. RESULTS: Overall, 1318 patients with SSc were included (mean age 58.3 ± 13.7 years, 81.3 % female), of whom 44 (3.3 %) were positive for NOR90. Of these, 32 were also positive for one of the SSc-criteria antibodies: 9/44 (20.5 %) for anti-topoisomerase I, 18/42 (42.9 %) for anti-centromere, and 5/40 (12.5 %) for anti-RNA polymerase III. NOR90-positive patients were more frequently female, had lower modified Rodnan skin score (mRSS), and lower prevalence of upper and lower gastrointestinal (GI) symptoms compared to NOR90-negative patients. In multivariable analysis, NOR90 remained significantly associated with lower mRSS and less frequent GI symptoms. The literature search identified 17 articles, including a total number of 87 NOR90-positive out of 3357 SSc patients, corresponding to an overall prevalence of 2.6 %. CONCLUSION: To our best knowledge, this is the largest SSc cohort tested for NOR90 to date, confirming the NOR90 prevalence in SSc patients is around 3 %.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a systémová sklerodermie $x imunologie $7 D012595
- 650 12
- $a antinukleární protilátky $x krev $7 D000974
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a DNA-topoisomerasy I $x imunologie $7 D004264
- 650 _2
- $a klinická relevance $7 D000092522
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Vonk, M C $u Department of the Rheumatology, Radboud University Nijmegen Medical Centre Huispost 667, 6500HB Nijmegen, the Netherlands
- 700 1_
- $a Garaiman, A $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland
- 700 1_
- $a Kersten, B E $u Department of the Rheumatology, Radboud University Nijmegen Medical Centre Huispost 667, 6500HB Nijmegen, the Netherlands
- 700 1_
- $a Becvar, R $u Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University - Na Slupi 4, 12800 Praha 2, Czechia
- 700 1_
- $a Tomcik, M $u Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University - Na Slupi 4, 12800 Praha 2, Czechia
- 700 1_
- $a Hoffmann-Vold, A-M $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland; Department of Rheumatology, Rikshospitalet University Hospital - Sognsvannveien 20, 0027 Oslo, Norway
- 700 1_
- $a Castellvi, I $u Department of Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167 Barcelona, Spain
- 700 1_
- $a Jaime, Jl Tandaipan $u Department of Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167 Barcelona, Spain
- 700 1_
- $a Brzosko, M $u Department of Internal Medicine Rheumatology Diabetology Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland
- 700 1_
- $a Milchert, M $u Department of Internal Medicine Rheumatology Diabetology Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland
- 700 1_
- $a Krasowska, D $u Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Staszica 11L, 20-081 Lublin, Poland
- 700 1_
- $a Michalska-Jakubus, M $u Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Staszica 11L, 20-081 Lublin, Poland
- 700 1_
- $a Airo, P $u 9 Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123 Brescia, Italy
- 700 1_
- $a Matucci-Cerinic, M $u Department of Experimental and Clinical Medicine, University of Florence & Division of Rheumatology AOUC, Florence, Italy; Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Bruni, C $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland; Department of Experimental and Clinical Medicine, University of Florence & Division of Rheumatology AOUC, Florence, Italy
- 700 1_
- $a Iudici, M $u Rheumatology Unit, Geneva University Hospitals, 1211 Geneva 14, Switzerland
- 700 1_
- $a Distler, Jhw $u Department of Rheumatology, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany
- 700 1_
- $a Gheorghiu, A M $u Department of Internal Medicine and Rheumatology Clinic, Ion Cantacuzino Hospital - Ion Movila Street 5-7, 020475 Bucharest, Romania
- 700 1_
- $a Poormoghim, H $u Department of Rheumatology, Firoozgar Hospital - Beh Afarin street, Tehran, Iran
- 700 1_
- $a Motta, F $u Department of Biomedical Sciences, Humanitas University, via R Levi Montalcini, 20090, Pieve Emanuele, Italy; Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, via A Manzoni 56, 20089, Rozzano, Milan, Italy
- 700 1_
- $a De Santis, M $u Department of Biomedical Sciences, Humanitas University, via R Levi Montalcini, 20090, Pieve Emanuele, Italy; Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, via A Manzoni 56, 20089, Rozzano, Milan, Italy
- 700 1_
- $a Parvu, M $u Department of Rheumatology, Colentina Clinical Hospital, 19-21 Stefan cel Mare, 020125 Bucharest, Romania
- 700 1_
- $a Distler, O $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland
- 700 1_
- $a Mihai, C $u Department of Rheumatology, University Hospital Zurich, University of Zurich, Rämistrasse 100, CH-8091 Zürich, Switzerland
- 773 0_
- $w MED00001627 $t European journal of internal medicine $x 1879-0828 $g Roč. 125 (20240409), s. 104-110
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38599922 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110848 $b ABA008
- 999 __
- $a ok $b bmc $g 2202260 $s 1231904
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 125 $c - $d 104-110 $e 20240409 $i 1879-0828 $m European journal of internal medicine $n Eur J Intern Med $x MED00001627
- LZP __
- $a Pubmed-20241015
